Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for myeloma: experimental drug etentamig enters human trials

NCT ID NCT06892522

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests an experimental drug, etentamig, in people with multiple myeloma, a blood cancer. The drug is given alone or with other cancer medicines. The goal is to see if it is safe and works against the cancer. About 440 adults will take part at sites worldwide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Etentamig (given alone or with lenalidomide, dexamethasone, daratumumab, or carfilzomib)
What this could lead to
If successful, this could provide a new treatment option for multiple myeloma, especially for patients whose cancer has returned or not responded to other therapies.
What could go wrong
This is an early-phase trial (phase 1/2), so safety and effectiveness are not yet proven. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 602 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern cooperative oncology group (ECOG) performance of \<= 1. * Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or relapsed or refractory (RR) MM, depending on the substudy. Exclusion Criteria: * Participant who has known active central nervous system involvement of MM. * Participant who has known active infection as outlined in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    34 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atrium Health Levine Cancer Institute /ID# 276193

    RECRUITING

    Charlotte, North Carolina, 28204-2990, United States

  • Atrium Health Wake Forest Baptist Medical Center /ID# 274847

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911

    RECRUITING

    Irvine, California, 92618, United States

  • City of Hope National Medical Center /ID# 273132

    RECRUITING

    Duarte, California, 91010, United States

  • Coffs Harbour Health Campus /ID# 272010

    RECRUITING

    Coffs Harbour, New South Wales, 2450, Australia

  • Colorado Blood Cancer Institute /ID# 273129

    RECRUITING

    Denver, Colorado, 80218, United States

  • Hadassah Medical Center-Hebrew University /ID# 271362

    RECRUITING

    Jerusalem, 91120, Israel

  • Hammersmith Hospital /ID# 274615

    RECRUITING

    London, England, W12 0HS, United Kingdom

  • Huntsman Cancer Institute /ID# 272575

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Icon Cancer Care - South Brisbane /ID# 271836

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Moffitt Cancer Center /ID# 272628

    RECRUITING

    Tampa, Florida, 33612, United States

  • Mount Sinai - The Tisch Cancer Institute /ID# 272470

    RECRUITING

    New York, New York, 10029, United States

  • Nagoya City University Hospital /ID# 273529

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • Oncology Hematology Care - Blue Ash /ID# 272918

    RECRUITING

    Cincinnati, Ohio, 45252, United States

  • Oslo Universitetssykehus Ulleval /ID# 277915

    RECRUITING

    Oslo, 0450, Norway

  • Peter MacCallum Cancer Centre. /ID# 272024

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Port Macquarie Base Hospital /ID# 275925

    RECRUITING

    Port Macquarie, New South Wales, 2444, Australia

  • Rabin Medical Center. /ID# 271365

    RECRUITING

    Petah Tikva, Central District, 4941492, Israel

  • Rambam Health Care Campus- Haifa /ID# 271364

    RECRUITING

    Haifa, 3109601, Israel

  • Royal Adelaide Hospital /ID# 272629

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Soroka Medical Center /ID# 271367

    RECRUITING

    Beersheba, Southern District, 8410101, Israel

  • St Vincent's Hospital - Melbourne /ID# 276451

    RECRUITING

    Fitzroy, Victoria, 3065, Australia

  • The Chaim Sheba Medical Center /ID# 271366

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The Ohio State University /ID# 271336

    RECRUITING

    Columbus, Ohio, 43210, United States

  • The Perth Blood Institute - West Perth /ID# 272469

    RECRUITING

    West Perth, Western Australia, 6005, Australia

  • The University of Osaka Hospital /ID# 275791

    RECRUITING

    Suita-shi, Osaka, 565-0871, Japan

  • University Hospital Kyoto Prefectural University of Medicine /ID# 275713

    RECRUITING

    Kyoto, Kyoto, 602-8566, Japan

  • University Hospital of Wales /ID# 273446

    RECRUITING

    Cardiff, CF14 4XW, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust /ID# 274620

    RECRUITING

    Birmingham, B15 2TG, United Kingdom

  • University of North Carolina at Chapel Hill /ID# 274667

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Texas - Southwestern Medical Center /ID# 274360

    RECRUITING

    Dallas, Texas, 75235, United States

  • Weill Cornell Medical College /ID# 272517

    RECRUITING

    New York, New York, 10065, United States

  • Westmead Hospital /ID# 271880

    RECRUITING

    Westmead, New South Wales, 2145, Australia

  • Winship Cancer Institute of Emory University /ID# 274830

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.